Edition:
United Kingdom

Pharmaceuticals

ViiV Healthcare Says To Develop Investigational Antibody N6lS For Treatment Of HIV-1

Nov 21 (Reuters) - ViiV Healthcare: :VIIV HEALTHCARE - TO DEVELOP INVESTIGATIONAL BROADLY NEUTRALISING ANTIBODY N6LS FOR TREATMENT AND PREVENTION OF HIV-1.VIIV HEALTHCARE - DEVELOPMENT OF INVESTIGATIONAL BNAB PART OF LICENSING DEAL BETWEEN GSK, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS...

1:54pm GMT

AFT Pharmaceuticals Says Signed Licensing Agreements For Maxigesic Pain Relief Medication

Nov 18 (Reuters) - AFT Pharmaceuticals Ltd ::SIGNED LICENSING AGREEMENTS FOR MAXIGESIC PAIN RELIEF MEDICATION IN GERMANY, PAKISTAN AND VIETNAM.AFT EXPECTS FIRST SALES OF MAXIGESIC IN GERMAN MARKET IN 2020 CALENDAR YEAR.SALES IN PAKISTAN & VIETNAM ARE EXPECTED IN 2022 AND ARE STILL DEPENDENT ON...

Sunday, 17 Nov 2019

AstraZeneca Releases Subgroup Analysis of TWILIGHT Trial Patients With NSTE-ACS

Nov 17 (Reuters) - AstraZeneca PLC ::SUBGROUP ANALYSIS OF TWILIGHT TRIAL PATIENTS WITH NON-ST ELEVATION ACUTE CORONARY SYNDROME (NSTE-ACS) WHO UNDERWENT PCI SHOWED BRILINTA MONOTHERAPY REDUCED THE RISK OF CLINICALLY RELEVANT BLEEDING COMPARED WITH DUAL ANTIPLATELET THERAPY...

Sunday, 17 Nov 2019

AstraZeneca Says Consistent Effects Of FARXIGA In Heart Failure Patients With Reduced Ejection Fraction Shown In New Analyses

Nov 17 (Reuters) - AstraZeneca PLC ::CONSISTENT EFFECTS OF FARXIGA IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION SHOWN IN NEW ANALYSES FROM LANDMARK PHASE III DAPA-HF TRIAL.ASTRAZENECA -FARXIGA SHOWED IMPROVEMENTS VERSUS PLACEBO IN WORSENING OR PROGRESSION OF DISEASE & IMPROVED...

Sunday, 17 Nov 2019

Expansion & New Markets

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.